Phaseline

Targets › NOS1

NOS1 (Nitric oxide synthase 1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 1 Phase 4, 1 Phase 2, 1 Phase 1; Genitourinary, Oncology, Cardiovascular; next expected readout Dec 2026.

Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. (UniProt, P29475)

Open in Phaseline: the race on NOS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas at ArlingtonL-Arginine
Substrate for nitric oxide synthase; overcomes ADMA inhibition to restore NO production an
NOS1, NOS2, NOS3Phase 4Chronic Kidney DiseaseDec 2026
The Methodist Hospital Research InstituteTilarginine
Nitric oxide synthase inhibitor
NOS1, NOS2, NOS3Phase 2HER2-negative Breast CancerDec 2026
Louis MessinaL-Arginine
Substrate for nitric oxide synthase, increases nitric oxide production
NOS1, NOS2, NOS3Phase 1Claudication, IntermittentJul 2027

Conditions

Chronic Kidney Disease (1) HER2-negative Breast Cancer (1) Claudication, Intermittent (1)

Modalities

small molecule (3)

Companies

The University of Texas at Arlington (1) The Methodist Hospital Research Institute (1) Louis Messina (1)

Related targets

NOS2 (3) NOS3 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.